Eli Lilly and Co

LLY is in a Stage 3 distribution regime with a bearish medium-term bias underpinned by a terminal Double Top and repeated failures at the 9- and 21-EMA. In the short term, price is holding near the 50-DMA support without a clear bounce into the shorter EMAs, so execution is deferred into potential rallies into dynamic resistance around the 9/21 EMA zone for optimal trimming.

• ↑Q1 revenue of $19.8 B, up 20% YoY, led by obesity and diabetes medicines
• ↑EPS rose to $2.05 from $1.50 YoY, reflecting volume expansion in new therapies
• ↓High forward P/E and negative earnings yield cast valuation concerns